REGN Key Statistics, Chart & Performance
The current stock price of REGN is 726.21 USD. In the past month the price increased by 7.66%. In the past year, price decreased by -0.7%.
REGN Latest News, Press Relases and Analysis
REGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.98B | ||
| AMGN | AMGEN INC | 14.42 | 169.83B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.61 | 112.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 793.06 | 53.43B | ||
| INSM | INSMED INC | N/A | 40.49B | ||
| NTRA | NATERA INC | N/A | 32.17B | ||
| BIIB | BIOGEN INC | 10.61 | 26.05B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.37 | 20.88B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.23 | 15.52B |
Related stock screener links
About REGN
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591 US
CEO: Leonard S. Schleifer
Employees: 15106
Phone: 17813705000
REGENERON PHARMACEUTICALS / REGN FAQ
Can you describe the business of REGENERON PHARMACEUTICALS?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
What is the current price of REGN stock?
The current stock price of REGN is 726.21 USD. The price increased by 4.86% in the last trading session.
What is the dividend status of REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a dividend yield of 0.49%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of REGN stock?
REGN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is REGENERON PHARMACEUTICALS (REGN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on REGN.
Can you provide the number of employees for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) currently has 15106 employees.
Can you provide the ownership details for REGN stock?
You can find the ownership structure of REGENERON PHARMACEUTICALS (REGN) on the Ownership tab.
REGN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to REGN. When comparing the yearly performance of all stocks, REGN is one of the better performing stocks in the market, outperforming 79.25% of all stocks.
REGN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to REGN. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues.
REGN Financial Highlights
Over the last trailing twelve months REGN reported a non-GAAP Earnings per Share(EPS) of 45.01. The EPS decreased by -0.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.13% | ||
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.09 |
REGN Forecast & Estimates
36 analysts have analysed REGN and the average price target is 796.01 USD. This implies a price increase of 9.61% is expected in the next year compared to the current price of 726.21.
For the next year, analysts expect an EPS growth of -3.71% and a revenue growth 0.28% for REGN